|
1
|
Kirkali Z and Tuzel E: Transitional cell
carcinoma of the ureter and renal pelvis. Crit Rev Oncol Hematol.
47:155–169. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Huben RP, Mounzer AM and Murphy GP: Tumor
grade and stage as prognostic variables in upper tract urothelial
tumors. Cancer. 62:2016–2020. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hutchinson R, Haddad A, Saqalowsky A and
Margulis V: Upper tract urothelial carcinoma: Special
considerations. Clin Adv Hematol Oncol. 14:101–109. 2016.PubMed/NCBI
|
|
4
|
Soderdahl DW, Fabrizio MD, Rahman NU,
Jarrett TW and Bagley DH: Endoscopic treatment of upper tract
transitional cell carcinoma. Urol Oncol. 23:114–122. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Cozad SC, Smalley SR, Austenfeld M, Noble
M, Jennings S and Raymond R: Adjuvant radiotherapy in high stage
transitional cell carcinoma of the renal pelvis and ureter. Int J
Radiat Oncol Biol Phys. 24:743–745. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Czito B, Zietman A, Kaufman D, Skowronski
U and Shipley W: Adjuvant radiotherapy with and without concurrent
chemotherapy for locally advanced transitional cell carcinoma of
the renal pelvis and ureter. J Urol. 172:1271–1275. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ding T, Zheng Z, Xu R and Zhou C:
Prognostic factors and outcomes of primary transitional cell
carcinoma of the ureter: A population-based study. Oncotarget.
8:65983–65996. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
DeLaney TF, Trofimov AV, Engelsman M and
Suit HD: Advanced-technology radiation therapy in the management of
bone and soft tissue sarcomas. Cancer Control. 12:27–35. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Inada T, Hayakawa Y, Tada J, Takada Y and
Maruhashi A: Characteristics of proton beams after field shaping at
PMRC. Med Biol Eng Comput. 31 (Suppl):S44–S48. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Iwata H, Ishikawa H, Takagi M, Okimoto T,
Murayama S, Akimoto T, Wada H, Arimura T, Sato Y, Araya M, et al:
Long-term outcomes of proton therapy for prostate cancer in Japan:
A multi-institutional survey of the Japanese Radiation Oncology
Study Group. Cancer Med. 7:677–689. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ha B, Cho KH, Lee KH, Joung JY, Kim YJ,
Lee SU, Kim H, Suh YG, Moon SH, Lim YK, et al: Long-term results of
a phase II study of hypofractionated proton therapy for prostate
cancer: Moderate versus extreme hypofractionation. Radiat Oncol.
14:42019. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Verma V, Simone CB II and Mishra MV:
Quality of life and patient-reported outcomes following proton
radiation therapy: A systematic review. J Natl Cancer Inst.
110:2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Takaoka EI, Miyazaki J, Ishikawa H, Kawai
K, Kimura T, Ishitsuka R, Kojima T, Kanuma R, Takizawa D, Okumura
T, et al: Long-term single-institute experience with trimodal
bladder-preserving therapy with proton beam therapy for
muscle-invasive bladder cancer. Jpn J Clin Oncol. 47:67–73. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hata M, Miyanaga N, Tokuuye K, Saida Y,
Ohara K, Sugahara S, Kagei K, Igaki H, Hashimoto T, Hattori K, et
al: Proton beam therapy for invasive bladder cancer: A prospective
study of bladder-preserving therapy with combined radiotherapy and
intra-arterial chemotherapy. Int J Radiat Oncol Biol Phys.
64:1371–1379. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Maehata Y, Kuriyama K, Aoki S, Araya M,
Marino K and Onishi H: Stereotactic body radiotherapy for localized
ureter transitional cell carcinoma: Three case reports. Case Rep
Urol. 2015:5198972015.PubMed/NCBI
|
|
16
|
Evans JD, Hansen CC, Tollefson MK and
Hallemeier CL: Stereotactic body radiation therapy for medically
inoperable, clinically localized, urothelial carcinoma of the renal
pelvis: A case report. Adv Radiat Oncol. 3:57–61. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Oshiro Y, Mizumoto M, Okumura T, Fukuda K,
Fukumitsu N, Abei M, Ishikawa H, Takizawa D and Sakurai H: Analysis
of repeated proton beam therapy for patients with hepatocellular
carcinoma. Radiother Oncol. 123:240–245. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Okonogi N, Hashimoto T, Ishida M, Ohno T,
Terunuma T, Okumura T, Sakae T and Sakurai H: Designed-seamless
irradiation technique for extended whole mediastinal proton-beam
irradiation for esophageal cancer. Radiat Oncol. 7:1732012.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ishikawa H, Hashimoto T, Moriwaki T, Hyodo
I, Hisakura K, Terashima H, Ohkohchi N, Ohno T, Makishima H,
Mizumoto M, et al: Proton beam therapy combined with concurrent
chemotherapy for esophageal cancer. Anticancer Res. 35:1757–1762.
2015.PubMed/NCBI
|
|
20
|
Rouprêt M, Babjuk M, Compérat E, Zigeuner
R, Sylvester RJ, Burger M, Cowan NC, Böhle A, Van Rhijn BW,
Kaasinen E, et al: European association of urology guidelines on
upper urinary tract urothelial cell carcinoma: 2015 update. Eur
Urol. 68:868–879. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Charbit L, Gendroau MC, Mee S and Cukier
J: Tumors of the upper urinary tract: 10 years of experience. J
Urol. 146:1243–1246. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Miyao N, Masumori N, Takahashi A, Sasai M,
Hisataki T, Kitamura H, Satoh M and Tsukamoto T: Lymph nodde
metastasis in patients with carcinomas of the renal pelvis and
ureter. Eur Urol. 33:180–185. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yang D, Chen Q, Song X, Wang J, Che X, Zhu
Z, Zheng W and Wang L: Effect of lymph node dissection on the
outcomes of upper tract urothelial carcinomas: A meta-analysis.
Expert Rev Anticancer Ther. 14:667–675. 2014. View Article : Google Scholar : PubMed/NCBI
|
